The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations

Laura J. Vella, Miles C. Andrews, Anupama Pasam, Katherine Woods, Andreas Behren, Jonathan S. Cebon

Research output: Contribution to journalArticleOtherpeer-review

10 Citations (Scopus)


Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.

Original languageEnglish
Article numbere946367
Number of pages3
Issue number7
Publication statusPublished - 1 Jan 2014
Externally publishedYes


  • BRAF
  • Dendritic cells
  • MEK
  • Melanoma
  • T-lymphocytes

Cite this